Our technology
Assay Development & Validation
We create complex cellular and patient-based cellular assays with a focus on robustness and high-throughput scalability to conduct large scale phenotypic screening, using a range of potential modalities, eg small molecular compound libraries, siRNA, ASOs. From the start we focus on phenotypic readouts using microscopic imaging. To ensure the relevance of our findings, we customize combinations of biochemical tests, functional readouts and disease specific tool compounds for a final pharmacological validation.
Image & Data Mining
Data is at the heart of what we do at Ksilink. Critically, dedicated AI algorithms (see on the right) allow the fast and precise classification of compounds for their ability to shift diseased-like phenotypes towards the healthy control. CRISPR screens even allow for a simultaneous identification of relevant compounds and their corresponding targets. Knowledge graphs are used for dataset integration and decision finding to select most relevant targets and candidates.
High-Throughput Phenotypic Screening
Our sterile robotic screening facility allows high-throughput, image-based screening of a range of complex cellular models including patient-based assays over extended periods. In parallel, Ksilink has secured access to large scale, quality controlled and standardized production of differentiated, patient iPSC-based material. Together, it allows for high-throughput screening and AI boosted analyses directly in the relevant disease model, performing the discovery process in a “human proof-of-concept” setting.
Our unique capacity ensures that our findings are highly disease relevant.